Epsilen Bio

Milano, Italy Founded: 2019 • Age: 7 yrs Acquired By Chroma Medicine
Epigenetic gene silencing technologies are developed for disease treatments.

About Epsilen Bio

Epsilen Bio is a Healthcare company based in Milano (Italy) founded in 2019 by Angelo Lombardo and Luigi Naldini, and was acquired by Chroma Medicine in November 2021. Epigenetic gene silencing technologies are developed for disease treatments. Its chief executive, as recorded, is Julia Berretta. Epsilen Bio offers products and services including Epigenetic Silencing. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Technology Platforms.

Company details

Founded in 2019 in Milano, Italy, Epsilen Bio operates in the biotechnology sector, where therapies are developed using Epigenetic Transcriptional Repressors (ETRs) for gene silencing. These approaches target inherited genetic diseases, cancer, autoimmune conditions, degenerative disorders, and viral infections. Operations focus on advancing clinical applications through innovative epigenetic mechanisms, with leadership provided by co-founders Angelo Lombardo and Luigi Naldini, alongside CEO Julia Berretta.

  • Headquarters Milano, Italy
  • Founders Angelo Lombardo, Luigi Naldini
  • Stage Acquired
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website epsilenbio.com
  • Acquired by Chroma Medicine (Nov 2021)
Key Metrics

Products & Services of Epsilen Bio

Epsilen Bio offers a comprehensive portfolio of products and services, including Epigenetic Silencing.

Epigenetic Silencing
Biotechnology

Method to treat human diseases via epigenetic techniques.

Funding Insights of Epsilen Bio

  • Total Rounds 1
  • Investors Count 1

All 1 funding rounds of Epsilen Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Apr 2020Seed–Sofinnova Partners
–
Valuation history

2 investors in total: 2 institutional.

Investors in Epsilen Bio

Epsilen Bio has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Chroma Medicine and Sofinnova Partners.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
Sofinnova Partners is focused on life sciences and healthcare investments.
sofinnovapartners.comParis, France
Epigenetic editing platform is developed for genomic medicines.
2020chromamedicine.comCambridge, United States
Premium access

Investor details for Epsilen Bio

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Epsilen Bio

26 people are tracked at Epsilen Bio (8 in leadership, 8 in board & advisors, 10 in team).

NameRoleGroup
Angelo Lombardo
Co-FounderLeadership
Luigi Naldini
Co-FounderLeadership
Julia Berretta
CEOLeadership
Sivan Harel
Director, Translational Biomarkers & BioanalyticsLeadership
Cecilia Fernandez
VP, Strategic Planning & OperationsLeadership
Tobias Brambrink
VP, Intellectual PropertyLeadership
Sahar Abubucker
VP, Data SciencesLeadership
Adam Connelly
Director Of Quality ControlLeadership
Howard Chang
AdvisorBoard & advisors
Luke Gilbert
FounderBoard & advisors
J. Keith Joung
FounderBoard & advisors
Jonathan Weissman
FounderBoard & advisors
Ahmad Khalil
AdvisorBoard & advisors
David Liu
FounderBoard & advisors
Bradley Bernstein
AdvisorBoard & advisors
Paula Cannon
AdvisorBoard & advisors
Melissa Pannone
Associate Scientist ITeam
Kyle Runckel
Scientist IITeam
Hasit Lunagaria
SVP, People & CultureTeam
Lenka Kundrat Hoffman
Principal ScientistTeam

6 more people are available in the full profile.

Premium access

Complete people profiles for Epsilen Bio

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Epsilen Bio

3 dated milestones of Epsilen Bio across 2 years, from founding to its latest funding, stage changes and deals.

  1. Founded Epsilen Bio is founded.
  2. Funding First funding round.
  3. Exit Acquired by Chroma Medicine.
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Epsilen Bio

Premium access

Complete news archive for Epsilen Bio

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Epsilen Bio

Epsilen Bio was founded in 2019 and raised its 1st funding round 1 year after it was founded.

Epsilen Bio is headquartered in Milano, Italy.

Julia Berretta is the CEO of Epsilen Bio, as recorded in our data.

Founded in 2019 in Milano, Italy, Epsilen Bio operates in the biotechnology sector, where therapies are developed using Epigenetic Transcriptional Repressors (ETRs) for gene silencing. These approaches target inherited genetic diseases, cancer, autoimmune conditions, degenerative disorders, and viral infections. Operations focus on advancing clinical applications through innovative epigenetic mechanisms, with leadership provided by co-founders Angelo Lombardo and Luigi Naldini, alongside CEO Julia Berretta.

Epsilen Bio offers Epigenetic Silencing.

Epsilen Bio has 2 investors. Key investors include Chroma Medicine, and Sofinnova Partners.

Yes. Epsilen Bio was acquired by Chroma Medicine in November 2021.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available